Clinical trials: Antibody Response After Vaccination
HIV
MMR Vaccination Among HIV-infected Adults
This is a prevalence study of protective antibodies to measles, mumps, and rubella (MMR) in HIV-infected adults and HIV-uninfected controls.
- Trial name
- NCT02724852
- Testing
- 0.5 ml of MMR vaccine
- Where
- Thailand
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
Infection
Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS
This study was aimed evaluate long-term immunity response by neutralizing antibody test of adults in high risk population of HFRS .
- Trial name
- NCT02360514
- Testing
- Hantavax injection
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Hepatitis B
Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination
This phase IV open study will evaluate the persistence of humoral antibodies against hepatitis B as well as the immune response to a challenge dose of hepatitis B vaccine in adolescents aged 12-13 years, who received three…
- Trial name
- NCT00984139
- Testing
- Engerix™-B Kinder
- Where
- 24 sites in Germany
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid…
- Trial name
- NCT00279734
- Testing
- Tetanus + pnemococcal vaccines alone, Abatacept + vaccines
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
COVID-19
Pilot Trial on Immunosuppression Modulation to Increase SARS-CoV-2 Vaccine Response in Kidney Transplant Recipients
Mycophenolate has been identified as risk factor for non-response to SARS-CoV-2 vaccination in kidney transplant recipients. Safety and efficacy of temporarily stopping of mycophenolate (or azathioprine) to increase vaccine…
- Trial name
- BOOST_TX_SubA (NCT05338177)
- Testing
- Immunosuppression reduction, No immunosuppression reduction
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Meningococcal Disease
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
One year antibody persistence after the fourth dose boost or two catch-up doses administered starting from 12 months of age and to evaluate the response to a a third dose boost or two catch-up dose starting at 24 months of age.
- Trial name
- NCT01139021
- Testing
- rMenB+OMV NZ
- Where
- 19 sites in Czechia, Finland
- Volunteers
- 508 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
SARS-CoV-2 Vaccination, Liver Transplantation
Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients
To investigate the variations in the humoral response to vaccines for the prevention of COVID-19 in liver transplant patients based on the type of immunosuppressive therapy adopted (tacrolimus based vs no-tacrolimus based) and…
- Trial name
- NCT05490342
- Testing
- Immunoassay, by ECLIA, for the quantitative in vitro determination of antibodies (including IgG) to the SARS - CoV - 2 spike protein (S) anti-RBD (receptor-binding domain) in serum and plasma samples.
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- University of Rome Tor Vergata
Lymphoma
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation
The purpose of this study is to determine if higher absolute lymphocyte count in the infused stem cell autograft (A-ALC) will lead to an improved antibody response to post-transplant immunization with Pneumococcal Conjugate…
- Trial name
- NCT00889278
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
COVID-19 Vaccine
SARS-CoV-2 Antibody Response in Children Aged 5-11 Years Following Vaccination Against COVID-19
There are few data on the immunogenicity of the Pfizer-Biontec BNT162b2 vaccine for the prevention of COVID-19 disease and of side effects in children aged 5-11 years.
- Trial name
- NCT05175989
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Rabin Medical Center
Anti-SARS-CoV-2 Antibody Response
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular…
- Trial name
- CoVVacBoost (NCT05142540)
- Testing
- blood and saliva samples will be taken
- Where
- Austria
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223)
The purpose of this study is to assess: TBE antibody persistence 24, 34, 46 and 58 months (as applicable) after the first booster TBE vaccination with FSME-IMMUN 0.5ml given in Study 223, by means of ELISA (IMMUNOZYM FSME IgG)…
- Trial name
- NCT00503529
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 2 sites in Poland
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19, Cancer
Antibodies Production After Covid-19 Vaccination Among Patients With Medical History of Cancer and Anti-CD-20 Treatment
This is a Phase II study designed to investigate if the Covid 19 vaccines are capable of eliciting production of antibodies against S protein of Sar-S-Cov-2 virus among patients with medical history of cancer previously treated…
- Conditions
- Covid19, Cancer, HIV Infections
- Trial name
- NCT04779996
- Testing
- Laboratory Samples
- Where
- Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Auxilio Mutuo Cancer Center
Rheumatoid Arthritis, Spondylarthropathy
Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®
Previous studies have analyzed serological responses following pneumococcal vaccination using 23-valent vaccination (Pneumovax) in Rheumatoid Arthritis (RA) patients that were on different therapeutic modalities including…
- Trial name
- PVA (NCT00828997)
- Testing
- Prevenar vaccination
- Where
- Sweden
- Volunteers
- 505 people
- Sponsor
- Region Skane
Covid19
Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infected, COVID-19 Convalescents…
- Trial name
- NCT04842305
- Testing
- Blood- and saliva tests
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lenanrt Friis-Hansen
Healthy Volunteers
A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects
The purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.
- Trial name
- NCT03895385
- Testing
- Bimekizumab
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Infections, Meningococcal
Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations
This is Phase IV, Open label, Multicenter study. Subject's parents and/or legal guardian will be provided information about the trial. If interested and if eligible, they will then be asked to provide signed informed consent.
- Trial name
- NCT02446691
- Testing
- MenACWY
- Where
- 6 sites in South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
In this extension study, V59P20E1, the sponsor was planning to assess 5-year antibody persistence in subjects who received one or two doses of MenACWY conjugate vaccine at 2 to 10 years of age, and to evaluate response to a…
- Trial name
- NCT01823536
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine
- Where
- 16 sites in United States, Ukraine
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Poliomyelitis, Vaccine Reaction
Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
Eupolio is inactivated poliovirus vaccine (IPV). Major purpose of this study is to evaluate safety of Eupolio in 2,000 infants. In addition to the safety, long-term protection after completion of the three primary vaccinations…
- Trial name
- NCT05431933
- Testing
- Eupolio
- Where
- 10 sites in Philippines, Thailand
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- LG Chem
Vaccine Reaction
Booster Effect of mRNA Vaccine on Antibody Response for SARS-CoV-2 After Complete Vaccination With Sinos
In most parts of the world, mRNA vaccines were used to provide protection to population against COVID 19. However, in some countries, including Pakistan, traditional viral vaccines named as Sinovac and Sinopharm were used for…
- Trial name
- NCT05213455
- Testing
- booster vaccine for COVID 19
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Lahore General Hospital
SARS-CoV-2
A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Kind
This study will investigate antibody levels with respect to time since receiving a COVID-19 booster shot. The study will be decentralized, where participants can complete all study tasks at home.
- Trial name
- disCOVEries (NCT05367908)
- Where
- United States
- Volunteers
- 1,501 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.